Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Mitochondrial DNA mutations are currently investigated as modifying factors impinging on tumor growth and aggressiveness, having been found in virtually all cancer types and most commonly affecting genes encoding mitochondrial complex I (CI) subunits. However, it is still unclear whether they exert a pro- or anti-tumorigenic effect. We here analyzed the impact of three homoplasmic mtDNA mutations (m.3460G>A/MT-ND1, m.3571insC/MT-ND1 and m.3243A>G/MT-TL1) on osteosarcoma progression, chosen since they induce different degrees of oxidative phosphorylation impairment. In fact, the m.3460G>A/MT-ND1 mutation caused only a reduction in CI activity, whereas the m.3571insC/MT-ND1 and the m.3243A>G/MT-TL1 mutations induced a severe structural and functional CI alteration. As a consequence, this severe CI dysfunction determined an energetic defect associated with a compensatory increase in glycolytic metabolism and AMP-activated protein kinase activation. Osteosarcoma cells carrying such marked CI impairment displayed a reduced tumorigenic potential both in vitro and in vivo, when compared with cells with mild CI dysfunction, suggesting that mtDNA mutations may display diverse impact on tumorigenic potential depending on the type and severity of the resulting oxidative phosphorylation dysfunction. The modulation of tumor growth was independent from reactive oxygen species production but correlated with hypoxia-inducible factor 1α stabilization, indicating that structural and functional integrity of CI and oxidative phosphorylation are required for hypoxic adaptation and tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 7×
“To induce a mild metabolic stress, cells were incubated in a DMEM without glucose supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin (LG).”
BackgroundInfluentialWallace, D. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3365 · Cited by 2,404
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“This transcription factor promotes the metabolic switch toward aerobic glycolysis or Warburg effect, promoting neo-vascularization, tumor progression and cell invasion (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Goto, Y.-I., Nonaka, I., & Horai, S. (1990) · Nature · doi:10.1038/348651a0 · Cited by 2,070
Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., & Hayashi, J.-I. (2008) · Science · doi:10.1126/science.1156906 · Cited by 1,444 · cited 4×
“Some studies reported that CI dysfunction, caused by mtDNA mutations, enhanced tumorigenic and metastatic potential in a ROS-dependent manner, by PI3K/Akt/PKC pathway activation and HIF1a over-expression (10,13,16,47).”
BackgroundInfluentialIsaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958 · cited 1×
“Such pseudohypoxic condition has been demonstrated in hereditary leiomyomatosis renal cell carcinoma, familial paraganglioma and familial pheochromocytoma patients, in which imbalance of TCA intermediates, namely fumarate and SA, affects PHD activity leading to a chronic stabilization of HIF1a (55,56).”
BackgroundHuman mitochondrial DNA: roles of inherited and somatic mutations
Schon, E. A., DiMauro, S., & Hirano, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3275 · Cited by 757 · cited 1×
“Isolated CI deficiencies, due to the occurrence of mitochondrial DNA (mtDNA) and nuclear DNA mutations, are the most frequent cause of mitochondrial diseases (2,3).”
BackgroundThe role of mitochondria in the pathogenesis of type 2 diabetes
Patti, M.-E., & Corvera, S. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0027 · Cited by 551
King, M. P., Koga, Y., Davidson, M., & Schon, E. A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.2.480 · Cited by 458
Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease
Distelmaier, F., Koopman, W. J. H., van den Heuvel, L. P., Rodenburg, R. J., Mayatepek, E., Willems, P. H. G. M., & Smeitink, J. A. M. (2008) · Brain · doi:10.1093/brain/awp058 · Cited by 310 · cited 1×
“Isolated CI deficiencies, due to the occurrence of mitochondrial DNA (mtDNA) and nuclear DNA mutations, are the most frequent cause of mitochondrial diseases (2,3).”
BackgroundThe Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling
Sullivan, L. B., Martinez-Garcia, E., Nguyen, H., Mullen, A. R., Dufour, E., Sudarshan, S., Licht, J. D., Deberardinis, R. J., & Chandel, N. S. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.003 · Cited by 304
Tong, W.-H., Sourbier, C., Kovtunovych, G., Jeong, S. Y., Vira, M., Ghosh, M., Romero, V. V., Sougrat, R., Vaulont, S., Viollet, B., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.018 · Cited by 212 · cited 1×
“Moreover, it has been shown in fumarate hydratase-deficient cells that AMPK can influence the PHDs activity and HIF1a stabilization by regulating cytosolic availability of iron, one of the essential cofactors of the hydroxylation reaction (57).”
BackgroundKoshikawa, N., Hayashi, J.-I., Nakagawara, A., & Takenaga, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054221 · Cited by 147
Cited by
Role of Glutathione in Cancer: From Mechanisms to Therapies
Kennedy, L., Sandhu, J. K., Harper, M.-E., & Cuperlovic-Culf, M. (2020) · Biomolecules · doi:10.3390/biom10101429 · Cited by 880
“rewiring mitochondrial metabolism, and the antitumorigenic effect of ROS signaling is lost [39].”
BackgroundMitochondrial reactive oxygen species and cancer
Sullivan, L. B., & Chandel, N. S. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-17 · Cited by 786
Functional Mitochondria in Health and Disease
Herst, P. M., Rowe, M. R., Carson, G. M., & Berridge, M. V. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00296 · Cited by 323
Non-Canonical Mechanisms Regulating Hypoxia-Inducible Factor 1 Alpha in Cancer
Iommarini, L., Porcelli, A. M., Gasparre, G., & Kurelac, I. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00286 · Cited by 231
Self-citationGenetic disorders coupled to ROS deficiency
O’Neill, S., Brault, J., Stasia, M.-J., & Knaus, U. G. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.009 · Cited by 164
Metadata
- Authors
- Iommarini, L., Kurelac, I., Capristo, M., Calvaruso, M. A., Giorgio, V., Bergamini, C., Ghelli, A., Nanni, P., De Giovanni, C., Carelli, V., Fato, R., Lollini, P. L., Rugolo, M., Gasparre, G., & Porcelli, A. M.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-24
- Volume
- 23
- Issue
- 6
- Pages
- 1453-1466
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2151568543
- Cited by
- 102
- References
- 17
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.